PTC Therapeutics (PTCT) said Thursday it has filed a new drug application with the US Food and Drug Administration for vatiquinone to treat children and adults with Friedreich's ataxia, a rare neuromuscular disorder.
The application is supported by data from the placebo-controlled MOVE-FA study and two long-term studies that show a "significant" reduction in disease progression and demonstrate a "safe and well-tolerated" vatiquinone across all age groups, the company said.
Price: 45.60, Change: +0.14, Percent Change: +0.31
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。